Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDX in Idiopathic Hypersomnia
NCT05668754Phase 2Completed
- Sponsor
- Zevra Therapeutics
- Start
- Dec 2022
- Primary completion
- Feb 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of serdexmethylphenidate in idiopathic hypersomnia (IH), sponsored by Zevra Therapeutics. Started Dec 2022; status: completed.
02
Drugs
serdexmethylphenidate
03
Conditions
idiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT05668754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668754.